🔊CEOInterviews

Eric Lefkofsky on precision medicine

From Tempus AI Investor Day 2026 | Precision Medicine Diagnostic Data Library Sells Fuel Growth Plans · · Investing 101

“I'm convinced where this is going is over the next several years we will begin to layer real world data insights on top of every biomarker that is really therapeutically relevant and so it will no longer be I sequence a non small cell lung cancer patient to see if they have EGFR ALK it will be once I know someone has EGFR ALK what does it mean are they going to be in the one quarter of patients that have almost no response, the one quarter of patients that'll be on that drug for 5 years, or the 50% of patients that'll be somewhere in between.”

Eric Lefkofsky
Cofounder, Tempus
precision medicinebiomarker insightstreatment response prediction

On , Eric Lefkofsky, Cofounder at Tempus, spoke about precision medicine during Tempus AI Investor Day 2026 | Precision Medicine Diagnostic Data Library Sells Fuel Growth Plans on Investing 101.

Tempus AI Investor Day 2026 | Precision Medicine Diagnostic Data Library Sells Fuel Growth Plans
Watch on YouTube at 1:58:30
Tempus AI Investor Day 2026 | Precision Medicine Diagnostic Data Library Sells Fuel Growth Plans
Investing 101
Watch on YouTube at 1:58:30
Tempus AI Investor Day 2026 | Precision Medicine Diagnostic Data Library Sells Fuel Growth Plans | May 29, 2026. Twitter -   / i101in   If you find our work useful, please support us by purchasing a Super Thanks— it truly helps us a lot. #earningscall #StockMarketNews #conferenceCall Earnings Call | Earnings Conference Call | Earnings concall | concall | quarterly results | Stock News | Full Year results | Fiscal Year results | investment news | stock latest news | Annual Meeting of Shareholders | Annual Meeting of Unitholders | Special and Annual Meeting of Shareholders | AGM | Annual General Meeting If you want us to remove your company's earnings call or any other conference call, please reach out to [email protected].
Eric Lefkofsky

About Eric Lefkofsky

Cofounder · Tempus

At Tempus AI’s 2026 Investor Day, Eric Lefkofsky described the company’s founding mission as using artificial intelligence to unlock precision medicine. He stated that Tempus has built a “connected ecosystem” that generates data from clinical workflows, turns that data into insights, and feeds those insights back into the healthcare system, which he called “sustainable.” Lefkofsky said the company’s data and modeling tools are used across the drug R&D lifecycle, from early-stage discovery through commercialization, and that Tempus licenses multimodal data to biopharma customers. Lefkofsky expressed confidence that data, AI, and technology will “permeate drug discovery and development and healthcare,” adding that “every industry who ever has said it’s not going to happen has been washed away by technology.” He predicted that real-world data insights will eventually be layered onto every therapeutically relevant biomarker. He also speculated that “there will come a time when no phase 3s ever fail,” attributing failures to either a misunderstood mechanism of action or a mismatch between phase 2 and phase 3 results.

Profile compiled from Eric Lefkofsky's verified public interviews and appearances. See all quotes & transcripts →

More from Eric Lefkofsky Full Transcript Explore All Executives